SCHEMBL5183035

SCHEMBL5183035

COc1ccc(CCN2CCN(c3ccc(Cl)c(F)c3)CC2)c(C)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ TGFBR1 P36897 1/20 0.40
▸ ACVR1 Q04771 1/20 0.40
▸ HTR4 Q13639 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ TP53BP1 Q12888 1/20 0.39
▸ L3MBTL3 Q96JM7 1/20 0.39
▸ MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5183561 0.90 LMNA (0.52) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5183909 0.89 LMNA (0.51) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6622755 0.86 LMNA (0.47) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6628361 0.85 LMNA (0.56) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6625036 0.84 LMNA (0.55) LMNAMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5182166 0.82 SIGMAR1 (0.53) TSHRSIGMAR1MAPK1
SCHEMBL5241842 0.81 LMNA (0.43) LMNAMAPTMEN1KMT2A
SCHEMBL5242970 0.81 LMNA (0.43) LMNAMAPT
SCHEMBL5243013 0.80 HTR1A (0.43) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL5242204 0.80 LMNA (0.42) LMNAMAPTMEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389189-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2004-02-18 — — EP claimed
WO-2002094799-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2002-11-28 — — WO claimed
EP-1729762-A4 COMBINATION THERAPY FOR WEIGHT MANAGEMENT NEUROGEN CORP (US) 2007-12-19 — — EP disclosed
EP-1729762-A2 COMBINATION THERAPY FOR WEIGHT MANAGEMENT NEUROGEN CORPORATION (US) 2006-12-13 — — EP disclosed
WO-2005094305-A2 COMBINATION THERAPY FOR WEIGHT MANAGEMENT NEUROGEN CORPORATION (US) 2005-10-13 — — WO disclosed
EP-1389189-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2004-02-18 — — EP disclosed
WO-2002094799-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2002-11-28 — — WO disclosed
Send feedback